(4-(4-pyridinyl)piperazinyl)(2-phenylquinazolinyl)ketone | 1361583-37-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: (4-(4-pyridinyl)piperazinyl)(2-phenylquinazolinyl)ketone
• 英文别名: (2-phenylquinazolin-4-yl)(4-(pyridin-4-yl)piperazin-1-yl)methanone；AD110；(2-Phenylquinazolin-4-yl)-(4-pyridin-4-ylpiperazin-1-yl)methanone
• CAS: 1361583-37-0
• 化学式: C₂₄H₂₁N₅O
• 分子量: 395.464
• InChiKey: LARKSTXSOAHAQU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  30
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  62.2
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  4-氯-2-苯基喹唑啉 在 草酰氯 、 水 、 对甲苯磺酸钠 、 三乙胺 、 N,N-二甲基甲酰胺 、 lithium hydroxide 作用下， 以 甲醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.0h， 生成 (4-(4-pyridinyl)piperazinyl)(2-phenylquinazolinyl)ketone
  参考文献：
  名称：

  Compound AD110 Acts as Therapeutic Management for Alzheimer’s Disease and Stroke in Mouse and Rat Models

  摘要：

  Anti-inflammatory therapy may be an effective therapeutic intervention for neurological diseases, such as Alzheimer's disease (AD) and stroke. As an important anti-inflammatory cytokine, interleukin-10 (IL-10) inhibits proinflammatory responses of both innate and adaptive immune cells. We tested the hypothesis that drug-induced promotion of IL-10 expression is effective in improving cognitive abilities and neurologic outcomes of AD and ury stroke. An orally small molecule AD110 was synthesized and subjected to in vitro and in vivo analyses. We found that AD110 enhanced IL-10 release in lipopolysaccharide (LPS)-activated BV2 microglial cells. Y-Maze and Morris water maze tests showed improved cognitive abilities in AD mice treated with AD110. Moreover, AD110 attenuated cerebral ischemic injury in a transient middle cerebral artery occlusion (tMCAO) rat model. This study not only provides a promising lead compound with IL-10-promoting activity, but also supports the hypothesis that promoting IL-10 expression is a potential therapeutic strategy for AD and stroke.

  DOI：

  10.1021/acschemneuro.9b00651

文献信息

• AMIDE COMPOUNDS
  申请人：Hu Wenhui

  公开号：US20130245033A1

  公开（公告）日：2013-09-19

  A compound represented by formula (I) and the pharmaceutical acceptable salt thereof are disclosed, wherein, R 1 , R 2 , R 3 , R 4 , R 5 and Ar are defined as those in the specification.

  公开了由化学式（I）表示的化合物及其药用可接受的盐，其中，R1、R2、R3、R4、R5和Ar的定义如规范中所述。
• US9238643B2
  申请人：——

  公开号：US9238643B2

  公开（公告）日：2016-01-19
• Compound AD110 Acts as Therapeutic Management for Alzheimer’s Disease and Stroke in Mouse and Rat Models
  作者：Ping Sun、Wei Zhou、Hu Yue、Cheng Zhang、Yitao Ou、Zhongjin Yang、Wenhui Hu

  DOI：10.1021/acschemneuro.9b00651

  日期：2020.3.18

  Anti-inflammatory therapy may be an effective therapeutic intervention for neurological diseases, such as Alzheimer's disease (AD) and stroke. As an important anti-inflammatory cytokine, interleukin-10 (IL-10) inhibits proinflammatory responses of both innate and adaptive immune cells. We tested the hypothesis that drug-induced promotion of IL-10 expression is effective in improving cognitive abilities and neurologic outcomes of AD and ury stroke. An orally small molecule AD110 was synthesized and subjected to in vitro and in vivo analyses. We found that AD110 enhanced IL-10 release in lipopolysaccharide (LPS)-activated BV2 microglial cells. Y-Maze and Morris water maze tests showed improved cognitive abilities in AD mice treated with AD110. Moreover, AD110 attenuated cerebral ischemic injury in a transient middle cerebral artery occlusion (tMCAO) rat model. This study not only provides a promising lead compound with IL-10-promoting activity, but also supports the hypothesis that promoting IL-10 expression is a potential therapeutic strategy for AD and stroke.